Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Galecto Inc (GLTO)

Galecto Inc (GLTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,827
  • Shares Outstanding, K 1,597
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,440 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta 1.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.70
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -12.10
  • Most Recent Earnings $-2.36 on 11/06/25
  • Next Earnings Date 03/18/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate $-0.14
  • Number of Estimates 1
  • High Estimate $-0.14
  • Low Estimate $-0.14
  • Prior Year $-5.22
  • Growth Rate Est. (year over year) +97.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.85 +44.53%
on 02/11/26
33.99 -15.59%
on 02/24/26
+4.69 (+19.54%)
since 02/09/26
3-Month
19.42 +47.73%
on 01/08/26
38.33 -25.14%
on 12/26/25
+0.90 (+3.24%)
since 12/09/25
52-Week
2.01 +1,327.36%
on 04/09/25
38.33 -25.14%
on 12/26/25
+24.63 (+606.65%)
since 03/07/25

Most Recent Stories

More News
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders

-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis...

GLTO : 28.69 (-0.76%)
Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted equity...

GLTO : 28.69 (-0.76%)
Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management...

GLTO : 28.69 (-0.76%)
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with...

GLTO : 28.69 (-0.76%)
Galecto Announces Pricing of $275 Million Underwritten Public Offering

BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with...

GLTO : 28.69 (-0.76%)
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with...

GLTO : 28.69 (-0.76%)
Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human...

GLTO : 28.69 (-0.76%)
Galecto Announces Key Additions to Leadership Team

Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class...

GLTO : 28.69 (-0.76%)
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant of non-qualified...

GLTO : 28.69 (-0.76%)
This Penny Stock Just Quadrupled. Should You Buy It Now?

Galecto stock skyrockets after announcing Damora Therapeutics acquisition. Here’s why GLTO shares are super unattractive to own at current levels.

GLTO : 28.69 (-0.76%)

Business Summary

Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters...

See More

Key Turning Points

3rd Resistance Point 34.54
2nd Resistance Point 32.47
1st Resistance Point 30.58
Last Price 28.69
1st Support Level 26.61
2nd Support Level 24.54
3rd Support Level 22.65

See More

52-Week High 38.33
Last Price 28.69
Fibonacci 61.8% 24.45
Fibonacci 50% 20.17
Fibonacci 38.2% 15.88
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.